BKM Wealth Management LLC Sells 1,238 Shares of Smith & Nephew SNATS, Inc. $SNN

BKM Wealth Management LLC lessened its stake in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 5.6% in the second quarter, HoldingsChannel reports. The firm owned 20,753 shares of the medical equipment provider’s stock after selling 1,238 shares during the period. BKM Wealth Management LLC’s holdings in Smith & Nephew SNATS were worth $636,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Ritholtz Wealth Management bought a new stake in Smith & Nephew SNATS in the 2nd quarter worth approximately $322,000. Moran Wealth Management LLC lifted its stake in shares of Smith & Nephew SNATS by 3.1% during the 2nd quarter. Moran Wealth Management LLC now owns 121,052 shares of the medical equipment provider’s stock valued at $3,708,000 after buying an additional 3,667 shares in the last quarter. Sequoia Financial Advisors LLC lifted its stake in Smith & Nephew SNATS by 56.3% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 11,645 shares of the medical equipment provider’s stock worth $357,000 after purchasing an additional 4,195 shares in the last quarter. Yousif Capital Management LLC purchased a new stake in Smith & Nephew SNATS in the 2nd quarter worth $217,000. Finally, Allspring Global Investments Holdings LLC lifted its stake in Smith & Nephew SNATS by 4.8% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 12,462 shares of the medical equipment provider’s stock worth $381,000 after purchasing an additional 570 shares in the last quarter. Institutional investors own 25.64% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on SNN shares. Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Wednesday, October 8th. Canaccord Genuity Group boosted their target price on shares of Smith & Nephew SNATS from $28.00 to $36.00 and gave the stock a “hold” rating in a report on Monday, August 18th. Sanford C. Bernstein set a $37.50 target price on shares of Smith & Nephew SNATS and gave the stock a “market perform” rating in a report on Tuesday. Finally, Wall Street Zen downgraded shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a report on Friday, October 3rd. Eight research analysts have rated the stock with a Hold rating, According to MarketBeat.com, Smith & Nephew SNATS has a consensus rating of “Hold” and a consensus price target of $36.75.

Smith & Nephew SNATS Price Performance

Shares of SNN stock opened at $36.35 on Friday. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40. The company has a market capitalization of $15.51 billion, a P/E ratio of 16.83, a P/E/G ratio of 0.99 and a beta of 0.69. The company’s 50-day simple moving average is $36.71 and its two-hundred day simple moving average is $31.73. Smith & Nephew SNATS, Inc. has a one year low of $23.69 and a one year high of $38.79.

Smith & Nephew SNATS Cuts Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Friday, November 7th. Stockholders of record on Friday, October 3rd will be given a $0.285 dividend. This represents a dividend yield of 165.0%. The ex-dividend date of this dividend is Friday, October 3rd. Smith & Nephew SNATS’s dividend payout ratio is presently 26.39%.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.